Source: Partridge AH al. Clin Oncol. 2014 Oct 10; 32 (29): 3307-29. (J)Recently, the American Society of Clinical Oncology (ASCO) released a
Source: Partridge AH al. Clin Oncol. 2014 Oct 10; 32 (29): 3307-29. (J)
Recently, the American Society of Clinical Oncology (ASCO) released a new clinical practice guidelines for the optimal treatment of advanced HER2 negative breast cancer.
ASCO guidelines for the treatment of advanced HER2 negative breast cancer with endocrine therapy and sequential chemotherapy based systemic therapy. Endocrine therapy should be a first-line treatment for patients with advanced hormone receptor positive breast cancer, according to the ASCO panel of experts. In addition to the following conditions: there are life-threatening, suspected endocrine therapy resistance. In order to reduce toxic side effects, the Group believes that sequential chemotherapy should be used instead of combination chemotherapy.
Partridge, the co chair of the steering group, and the Dana-Farber Cancer Institute at the Harvard University, said the goal of the guidelines is not only to improve the patient's survival time, but also to improve the quality of life of patients.
Premature Ejaculation,Tumour,Hypertension,Depression,Tumour,Andrology Diseases,Tumour,Arthritis,Pain,Deaf,。 Cure999
Cure999 @ 2018